skip to content
Primary navigation


Drug - Arcapta (indacaterol) [Novartis]

June 2012

Therapeutic area - COPD

Approval criteria

  • Patient has a diagnosis of COPD AND
  • Patient has tried and failed 2 of the following 3 drugs used for maintenance treatment of COPD: Serevent, Foradil, Spiriva

Quantity limit

Quantity Limit = 30

Background information

ARCAPTA NEOHALER is a long-acting beta2-adrenergic agonist indicated for: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top